FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2154753744> ?p ?o ?g. }

• W2154753744 endingPage "1755" @default.
• W2154753744 startingPage "1750" @default.
• W2154753744 abstract "BackgroundTremelimumab (CP-675,206) is a fully human monoclonal antibody binding to cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) on T cells that stimulates the immune system by blocking the CTLA4-negative regulatory signal. Combination with standard chemotherapy may strengthen antitumor therapy. This is a phase Ib, multisite, open-label, nonrandomized dose escalation trial evaluating the safety, tolerability, and maximum tolerated dose (MTD) of tremelimumab combined with gemcitabine in patients with metastatic pancreatic cancer.Patients and methodsGemcitabine (1000 mg/m2 on days 1, 8, and 15 of each 28-day cycles) was administrated with escalating doses of i.v. tremelimumab (6, 10, or 15 mg/kg) on day 1 of each 84-day cycle for a maximum of 4 cycles. The first 18 patients had an initial 4-week gemcitabine-only lead-in period. Dose-limiting toxicities (DLTs) related to tremelimumab were evaluated during the first 6 weeks after the first dose of tremelimumab.ResultsFrom June 2008 to August 2011, 34 patients were enrolled and received at least one dose of tremelimumab. No DLTs related to tremelimumab were observed at any dose, even when the maximum dose established for tremelimumab (15 mg/kg) was used. Most frequent grade 3/4 toxicities were asthenia (11.8%) and nausea (8.8%). Only one patient had a serious drug-related event (diarrhea with dehydration). The median overall survival was 7.4 months (95% confidence interval 5.8–9.4 months). At the end of treatment, two patients achieved partial response. Both patients received tremelimumab 15-mg/kg group (n = 2/19, 10.5%).ConclusionTremelimumab plus gemcitabine demonstrated a safety and tolerability profile, warranting further study in patients with metastatic pancreatic cancer.ClinicalTrials.gov IDNCT00556023." @default.
• W2154753744 created "2016-06-24" @default.
• W2154753744 creator A5005586870 @default.
• W2154753744 creator A5006501240 @default.
• W2154753744 creator A5009845881 @default.
• W2154753744 creator A5012297229 @default.
• W2154753744 creator A5012446712 @default.
• W2154753744 creator A5013289588 @default.
• W2154753744 creator A5022734154 @default.
• W2154753744 creator A5026093465 @default.
• W2154753744 creator A5045409190 @default.
• W2154753744 creator A5046444872 @default.
• W2154753744 creator A5056702454 @default.
• W2154753744 creator A5080676581 @default.
• W2154753744 creator A5089737299 @default.
• W2154753744 date "2014-09-01" @default.
• W2154753744 modified "2023-10-17" @default.
• W2154753744 title "A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer" @default.
• W2154753744 cites W1931508686 @default.
• W2154753744 cites W1965494873 @default.
• W2154753744 cites W1983923482 @default.
• W2154753744 cites W2004956320 @default.
• W2154753744 cites W2026707626 @default.
• W2154753744 cites W2031203833 @default.
• W2154753744 cites W2044363258 @default.
• W2154753744 cites W2066230562 @default.
• W2154753744 cites W2094366129 @default.
• W2154753744 cites W2097995306 @default.
• W2154753744 cites W2139248078 @default.
• W2154753744 cites W2140460887 @default.
• W2154753744 cites W2141579931 @default.
• W2154753744 cites W2151253787 @default.
• W2154753744 cites W2156253417 @default.
• W2154753744 cites W2159697541 @default.
• W2154753744 cites W2163184777 @default.
• W2154753744 cites W2165480504 @default.
• W2154753744 doi "https://doi.org/10.1093/annonc/mdu205" @default.
• W2154753744 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24907635" @default.
• W2154753744 hasPublicationYear "2014" @default.
• W2154753744 type Work @default.
• W2154753744 sameAs 2154753744 @default.
• W2154753744 citedByCount "162" @default.
• W2154753744 countsByYear W21547537442015 @default.
• W2154753744 countsByYear W21547537442016 @default.
• W2154753744 countsByYear W21547537442017 @default.
• W2154753744 countsByYear W21547537442018 @default.
• W2154753744 countsByYear W21547537442019 @default.
• W2154753744 countsByYear W21547537442020 @default.
• W2154753744 countsByYear W21547537442021 @default.
• W2154753744 countsByYear W21547537442022 @default.
• W2154753744 countsByYear W21547537442023 @default.
• W2154753744 crossrefType "journal-article" @default.
• W2154753744 hasAuthorship W2154753744A5005586870 @default.
• W2154753744 hasAuthorship W2154753744A5006501240 @default.
• W2154753744 hasAuthorship W2154753744A5009845881 @default.
• W2154753744 hasAuthorship W2154753744A5012297229 @default.
• W2154753744 hasAuthorship W2154753744A5012446712 @default.
• W2154753744 hasAuthorship W2154753744A5013289588 @default.
• W2154753744 hasAuthorship W2154753744A5022734154 @default.
• W2154753744 hasAuthorship W2154753744A5026093465 @default.
• W2154753744 hasAuthorship W2154753744A5045409190 @default.
• W2154753744 hasAuthorship W2154753744A5046444872 @default.
• W2154753744 hasAuthorship W2154753744A5056702454 @default.
• W2154753744 hasAuthorship W2154753744A5080676581 @default.
• W2154753744 hasAuthorship W2154753744A5089737299 @default.
• W2154753744 hasBestOaLocation W21547537441 @default.
• W2154753744 hasConcept C121608353 @default.
• W2154753744 hasConcept C126322002 @default.
• W2154753744 hasConcept C143998085 @default.
• W2154753744 hasConcept C197934379 @default.
• W2154753744 hasConcept C2776694085 @default.
• W2154753744 hasConcept C2777701055 @default.
• W2154753744 hasConcept C2778375690 @default.
• W2154753744 hasConcept C2778650287 @default.
• W2154753744 hasConcept C2780258809 @default.
• W2154753744 hasConcept C2781433595 @default.
• W2154753744 hasConcept C71924100 @default.
• W2154753744 hasConcept C90924648 @default.
• W2154753744 hasConceptScore W2154753744C121608353 @default.
• W2154753744 hasConceptScore W2154753744C126322002 @default.
• W2154753744 hasConceptScore W2154753744C143998085 @default.
• W2154753744 hasConceptScore W2154753744C197934379 @default.
• W2154753744 hasConceptScore W2154753744C2776694085 @default.
• W2154753744 hasConceptScore W2154753744C2777701055 @default.
• W2154753744 hasConceptScore W2154753744C2778375690 @default.
• W2154753744 hasConceptScore W2154753744C2778650287 @default.
• W2154753744 hasConceptScore W2154753744C2780258809 @default.
• W2154753744 hasConceptScore W2154753744C2781433595 @default.
• W2154753744 hasConceptScore W2154753744C71924100 @default.
• W2154753744 hasConceptScore W2154753744C90924648 @default.
• W2154753744 hasIssue "9" @default.
• W2154753744 hasLocation W21547537441 @default.
• W2154753744 hasLocation W21547537442 @default.
• W2154753744 hasLocation W21547537443 @default.
• W2154753744 hasOpenAccess W2154753744 @default.
• W2154753744 hasPrimaryLocation W21547537441 @default.
• W2154753744 hasRelatedWork W2024219304 @default.
• W2154753744 hasRelatedWork W2080820783 @default.

• next